Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03325114 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Chlorthalidone in Type 1 Diabetes
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03325114 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1 participants.
The verdict
NCT03325114, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
Interventions
- DRUG Chlorthalidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03325114
The ClinicalTrials.gov registry entry for NCT03325114 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chlorthalidone is the first listed.
NCT03325114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03325114 about?
NCT03325114 is a clinical study titled "Safety and Efficacy of Chlorthalidone in Type 1 Diabetes". This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
What is the current status of trial NCT03325114?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-06-28. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03325114?
The interventions under investigation include: Chlorthalidone (DRUG).
Who is sponsoring clinical trial NCT03325114?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.